28 May 2024
BIOPHARMA CREDIT PLC
UPDATE ON INVESTMENT
BioPharma Credit PLC (LSE: BPCR) notes the update on the UK CMA (Competition and Markets Authority) website made on 24 May 2024 regarding the status of its review of the acquisition of LumiraDx by Roche. The updated website can be found in its entirety at: UK CMA Roche / LumiraDx merger inquiry.
The acquisition of LumiraDx by Roche continues to undergo the standard process to receive antitrust and regulatory reviews. At this time, Pharmakon Advisors, LP cannot comment beyond what has been made public by the CMA and the companies involved in the transaction.
Pharmakon Advisors, LP is continuing to actively monitor the situation and will provide any updates in due course.
Enquiries
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0) 20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors
BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
